Begin main content

Lenvima for Hepatocellular Carcinoma – Details

Project Number pCODR 10175
Brand Name Lenvima
Generic Name Lenvatinib
Strength 4 mg & 12 mg
Tumour Type Gastrointestinal
Indication Hepatocellular Carcinoma
Funding Request For the first-line treatment of adult patients with unresectable Hepatocellular Carcinoma (HCC)
Review Status Open for Feedback on Recommendation
Pre Noc Submission No
NOC Date December 19, 2018
Manufacturer Eisai Limited
Submitter Eisai Limited
Submission Date February 8, 2019
Submission Deemed Complete February 25, 2019
Submission Type New Indication
Prioritization Requested
Stakeholder Input Deadline ‡ February 25, 2019
Check-point meeting April 12, 2019
pERC Meeting June 20, 2019
Initial Recommendation Issued July 5, 2019
Feedback Deadline ‡ July 19, 2019
pERC Reconsideration Meeting (target date)
Final Recommendation Issued (target date)
Notification to Implement Issued

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.